Ventricular Assist Device–Associated Thrombus
نویسندگان
چکیده
منابع مشابه
Thrombus in Ventricular Assist Device Patients
Background. Thromboembolic events may be related to thrombotic deposition on prosthetic valves. In a left ventricular assist device (LVAD) that contains two porcine pericardial bioprosthetic valves in addition to significant associated biomaterial placement, this may be particularly true. Thrombotic deposits on valves removed from LVADs at autopsy or heart transplantation were scored to determi...
متن کاملAn unusual presentation of left ventricular assist device thrombus.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . doi:10.1093/ehjci/jes011 Online publish-ahead-of-pr...
متن کاملRecurrent Early Thrombus Formation in HeartMate II Left Ventricular Assist Device
Left ventricular assist devices are becoming an established treatment for end-stage heart failure. In spite of their proven benefit, pump thrombosis remains a significant complication. Here we describe the challenging management of a patient with recurrent pump thrombosis.
متن کاملUnexpected bioprosthetic mitral valve thrombus during left ventricular assist device implantation
Acute bioprosthetic valve thrombosis can occur after surgery and sometimes cause hemodynamic instability and cardiogenic shock. Risk factors for bioprosthetic valve thrombosis are hypercoagulability, atrial fibrillation, atrial dilatation, low cardiac function, and lack of anticoagulation therapy. The authors present a case of severe mitral stenosis due to bioprosthetic valve thrombus. The pati...
متن کاملHigh fidelity computational simulation of thrombus formation in Thoratec HeartMate II continuous flow ventricular assist device
Continuous flow ventricular assist devices (cfVADs) provide a life-saving therapy for severe heart failure. However, in recent years, the incidence of device-related thrombosis (resulting in stroke, device-exchange surgery or premature death) has been increasing dramatically, which has alarmed both the medical community and the FDA. The objective of this study was to gain improved understanding...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2011
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.111.035337